NO944780L - Forhindring og behandling av perifer neuropati - Google Patents

Forhindring og behandling av perifer neuropati

Info

Publication number
NO944780L
NO944780L NO944780A NO944780A NO944780L NO 944780 L NO944780 L NO 944780L NO 944780 A NO944780 A NO 944780A NO 944780 A NO944780 A NO 944780A NO 944780 L NO944780 L NO 944780L
Authority
NO
Norway
Prior art keywords
peripheral neuropathy
prevention
treatment
igf
insulin
Prior art date
Application number
NO944780A
Other languages
English (en)
Other versions
NO309705B1 (no
NO944780D0 (no
Inventor
Michael E Lewis
Stuart C Apfel
John A Kessler
Original Assignee
Cephalon Inc
Einstein Coll Med
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US08/051,191 external-priority patent/US5420112A/en
Application filed by Cephalon Inc, Einstein Coll Med filed Critical Cephalon Inc
Publication of NO944780D0 publication Critical patent/NO944780D0/no
Publication of NO944780L publication Critical patent/NO944780L/no
Publication of NO309705B1 publication Critical patent/NO309705B1/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/30—Insulin-like growth factors, i.e. somatomedins, e.g. IGF-1, IGF-2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Diabetes (AREA)
  • Molecular Biology (AREA)
  • Endocrinology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Surgical Instruments (AREA)
  • External Artificial Organs (AREA)
  • Apparatus For Radiation Diagnosis (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)
NO944780A 1992-06-12 1994-12-09 Anvendelse av insulin-liknende vekstfaktor for fremstilling av et medikament for redusering av perifer neuropati NO309705B1 (no)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US89907092A 1992-06-12 1992-06-12
US08/051,191 US5420112A (en) 1992-06-12 1993-04-16 Prevention and treatment of peripheral neuropathy
PCT/US1993/005203 WO1993025219A1 (en) 1992-06-12 1993-06-01 Prevention and treatment of peripheral neuropathy

Publications (3)

Publication Number Publication Date
NO944780D0 NO944780D0 (no) 1994-12-09
NO944780L true NO944780L (no) 1994-12-09
NO309705B1 NO309705B1 (no) 2001-03-19

Family

ID=26729153

Family Applications (1)

Application Number Title Priority Date Filing Date
NO944780A NO309705B1 (no) 1992-06-12 1994-12-09 Anvendelse av insulin-liknende vekstfaktor for fremstilling av et medikament for redusering av perifer neuropati

Country Status (16)

Country Link
US (3) US5569648A (no)
EP (1) EP0659083B1 (no)
JP (1) JP3623502B2 (no)
AT (1) ATE187889T1 (no)
AU (1) AU683215B2 (no)
CA (1) CA2136969C (no)
DE (1) DE69327402T2 (no)
DK (1) DK0659083T3 (no)
ES (1) ES2140463T3 (no)
FI (1) FI945840A0 (no)
GR (1) GR3032844T3 (no)
HU (1) HU217543B (no)
NO (1) NO309705B1 (no)
NZ (2) NZ253867A (no)
PT (1) PT659083E (no)
WO (1) WO1993025219A1 (no)

Families Citing this family (68)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH09509140A (ja) * 1993-11-15 1997-09-16 セルトリックス ファーマシューティカルズ，インコーポレイテッド 神経学的障害の治療方法
US5728676A (en) * 1994-09-08 1998-03-17 Ciba-Geigy Corporation Use of insulin-like growth factors I and II for inhibition of inflammatory response
US5741776A (en) * 1995-05-22 1998-04-21 Genentech, Inc. Method of administration of IGF-I
US6121416A (en) 1997-04-04 2000-09-19 Genentech, Inc. Insulin-like growth factor agonist molecules
US6420518B1 (en) 1997-04-04 2002-07-16 Genetech, Inc. Insulin-like growth factor agonist molecules
US6403764B1 (en) 1999-01-06 2002-06-11 Genentech, Inc. Insulin-like growth factor-1 protein variants
EP0981545B1 (en) * 1997-05-05 2006-09-13 Mayo Foundation For Medical Education And Research IGFIIE/ IGFBP2 complex
US6548482B1 (en) 1997-05-05 2003-04-15 Mayo Foundation For Medical Education And Research Treatment of osteoporosis
US6916790B2 (en) 1997-05-05 2005-07-12 Mayo Foundation For Medical Education And Research Treatment of osteoporosis
WO1999018946A1 (en) 1997-10-14 1999-04-22 Tatton Nadine A Methods for increasing schwann cell survival
AU748143B2 (en) * 1997-10-28 2002-05-30 University Of British Columbia, The Immunological compositions and methods of use to transiently alter mammalian central nervous system myelin to promote neuronal regeneration
ES2146530B1 (es) * 1997-12-26 2001-04-16 Consejo Superior Investigacion Utilizacion del factor de crecimiento igf-i en la fabricacion de composiciones utiles en el tratamiento de la ataxia cerebelar.
US6043259A (en) * 1998-07-09 2000-03-28 Medicure Inc. Treatment of cardiovascular and related pathologies
EP1169322B8 (en) 1999-03-08 2006-09-13 Medicure Inc. Pyridoxal analogues for the treatment of disorders caused by a deficiency in vitamin b6
US20050008641A1 (en) * 1999-04-28 2005-01-13 University Of British Columbia Composition for neuronal regeneration comprising myelin-specific antibodies and complement proteins
EP1196171A2 (en) 1999-07-13 2002-04-17 Medicure Inc. Use of pyridoxin derivatives for the treatment of diabetes and related complications
EP1210117A2 (en) * 1999-08-24 2002-06-05 Medicure International Inc. Compositons for the treatment of cardiovascular diseases containing pyridoxal compounds and cardiovascular compounds
US6770468B1 (en) 1999-09-14 2004-08-03 Genzyme Glycobiology Research Institute, Inc. Phosphodiester-α-GlcNAcase of the lysosomal targeting pathway
US6642038B1 (en) 1999-09-14 2003-11-04 Genzyme Glycobiology Research Institute, Inc. GlcNAc phosphotransferase of the lysosomal targeting pathway
US6632429B1 (en) 1999-12-17 2003-10-14 Joan M. Fallon Methods for treating pervasive development disorders
DE60133323T2 (de) 2000-02-29 2009-03-05 Medicure International Inc. Cardioprotektive Phosphonate
US7442689B2 (en) * 2000-02-29 2008-10-28 Medicure International Inc. Cardioprotective phosphonates and malonates
JP2003528146A (ja) 2000-03-28 2003-09-24 メディキュア インターナショナル インコーポレイテッド 脳血管疾患の治療
WO2001087323A2 (en) 2000-05-16 2001-11-22 Genentech, Inc. Method for treating cartilage disorders
ATE364595T1 (de) 2000-07-07 2007-07-15 Medicure Int Inc Pyridoxin- und pyridoxalanaloga als cardiovasculäre therapeutika
US6897228B2 (en) * 2000-07-07 2005-05-24 Medicure International Inc. Pyridoxine and pyridoxal analogues: new uses
US6548519B1 (en) 2001-07-06 2003-04-15 Medicure International Inc. Pyridoxine and pyridoxal analogues: novel uses
WO2002014537A2 (en) * 2000-08-14 2002-02-21 Fallon Joan M Methods for diagnosing and treating dysautonomia and other dysautonomic conditions
US20070053895A1 (en) 2000-08-14 2007-03-08 Fallon Joan M Method of treating and diagnosing parkinsons disease and related dysautonomic disorders
US8030002B2 (en) 2000-11-16 2011-10-04 Curemark Llc Methods for diagnosing pervasive development disorders, dysautonomia and other neurological conditions
US7273698B2 (en) 2000-12-13 2007-09-25 Baylor College Of Medicine Defects in periaxin associated with myelinopathies
JP4489352B2 (ja) 2001-02-09 2010-06-23 ジェネンテック， インコーポレイテッド Ｉｇｆ−１の結晶化
US20040121988A1 (en) * 2001-03-28 2004-06-24 Medicure International Inc. Treatment of cerebrovascular disease
US7605177B2 (en) * 2001-05-24 2009-10-20 Neuren Pharmaceuticals Limited Effects of glycyl-2 methyl prolyl glutamate on neurodegeneration
ATE435852T1 (de) 2001-05-24 2009-07-15 Neuren Pharmaceuticals Ltd Gpe-analoga und peptidomimetika
US20070004641A1 (en) * 2001-05-24 2007-01-04 Neuren Pharmaceuticals Limited Cognitive enhancement and cognitive therapy using glycyl-L-2-methylprolyl-L-glutamate
US7714020B2 (en) * 2001-05-24 2010-05-11 Neuren Pharmaceuticals Limited Treatment of non-convulsive seizures in brain injury using G-2-methyl-prolyl glutamate
US6800472B2 (en) * 2001-12-21 2004-10-05 Genzyme Glycobiology Research Institute, Inc. Expression of lysosomal hydrolase in cells expressing pro-N-acetylglucosamine-1-phosphodiester α-N-acetyl glucosimanidase
US6905856B2 (en) 2001-12-21 2005-06-14 Genzyme Glycobiology Research Institute, Inc. Soluble GlcNAc phosphotransferase
US20030124652A1 (en) * 2001-12-21 2003-07-03 Novazyme Pharmaceuticals, Inc. Methods of producing high mannose glycoproteins in complex carbohydrate deficient cells
ES2207387B1 (es) * 2002-02-28 2005-07-16 Consejo Sup. Investig. Cientificas Composicion quimica de igf-i para el tratamiento y prevencion de enfermedades neurodegenerativas.
US20040186077A1 (en) * 2003-03-17 2004-09-23 Medicure International Inc. Novel heteroaryl phosphonates as cardioprotective agents
CN101014357A (zh) * 2004-07-07 2007-08-08 麦迪库瑞国际公司 利用血小板聚集药物的组合疗法
US20070060549A1 (en) * 2004-08-10 2007-03-15 Friesen Albert D Combination therapies employing ace inhibitors and uses thereof for the treatment of diabetic disorders
ES2788699T3 (es) * 2004-08-30 2020-10-22 Ipsen Biopharmaceuticals Inc Procedimiento y dispositivo para diagnosticar y tratar trastornos de deficiencia del factor de crecimiento similar a la insulina
US20060198838A1 (en) * 2004-09-28 2006-09-07 Fallon Joan M Combination enzyme for cystic fibrosis
US7459468B2 (en) * 2004-10-28 2008-12-02 Medicure International, Inc. Aryl sulfonic pyridoxines as antiplatelet agents
EP1817288A4 (en) * 2004-10-28 2009-08-26 Medicure Int Inc DUAL ANTIPLÄTTCHEN / ANTIKOAGULANS PYRIDOXINANALOGE
US20060094749A1 (en) * 2004-10-28 2006-05-04 Medicure International Inc. Substituted pyridoxines as anti-platelet agents
US20080058282A1 (en) 2005-08-30 2008-03-06 Fallon Joan M Use of lactulose in the treatment of autism
US20070116695A1 (en) * 2005-09-21 2007-05-24 Fallon Joan M Pharmaceutical preparations for attention deficit disorder, attention deficit hyperactivity disorder and other associated disorders
JP2009517411A (ja) * 2005-11-28 2009-04-30 メディキュア インターナショナル インコーポレーテッド 心血管及び関連病状の処置のための調剤
US8658163B2 (en) 2008-03-13 2014-02-25 Curemark Llc Compositions and use thereof for treating symptoms of preeclampsia
US8084025B2 (en) 2008-04-18 2011-12-27 Curemark Llc Method for the treatment of the symptoms of drug and alcohol addiction
US9320780B2 (en) * 2008-06-26 2016-04-26 Curemark Llc Methods and compositions for the treatment of symptoms of Williams Syndrome
ES2732453T3 (es) * 2008-07-01 2019-11-22 Curemark Llc Métodos y composiciones para el tratamiento de síntomas de trastornos neurológicos y de salud mental
US10776453B2 (en) * 2008-08-04 2020-09-15 Galenagen, Llc Systems and methods employing remote data gathering and monitoring for diagnosing, staging, and treatment of Parkinsons disease, movement and neurological disorders, and chronic pain
US20100092447A1 (en) 2008-10-03 2010-04-15 Fallon Joan M Methods and compositions for the treatment of symptoms of prion diseases
GB2480772B (en) 2009-01-06 2013-10-16 Curelon Llc Compositions and methods for the treatment or prevention of staphylococcus aureus infections and for the eradication or reduction of staphylococcus aureus
EP2373693A4 (en) 2009-01-06 2012-04-25 Curelon Llc COMPOSITIONS AND METHODS FOR THE TREATMENT OR PREVENTION OF ORAL INFECTIONS BY E. COLI
US9056050B2 (en) * 2009-04-13 2015-06-16 Curemark Llc Enzyme delivery systems and methods of preparation and use
US9511125B2 (en) 2009-10-21 2016-12-06 Curemark Llc Methods and compositions for the treatment of influenza
US20110217288A1 (en) * 2010-03-05 2011-09-08 Baylor Research Institute Involvement of Androgen/Androgen Receptor Pathway in Fabry Disease
CN103370074B (zh) * 2011-01-26 2015-09-02 雪印惠乳业株式会社 感觉改善剂
WO2012145651A2 (en) 2011-04-21 2012-10-26 Curemark, Llc Compounds for the treatment of neuropsychiatric disorders
EP2771367B1 (en) 2011-10-25 2017-12-06 Indiana University Research and Technology Corporation Gigaxonin fusion protein and methods for treating giant axonal neuropathy
US10350278B2 (en) 2012-05-30 2019-07-16 Curemark, Llc Methods of treating Celiac disease
US11541009B2 (en) 2020-09-10 2023-01-03 Curemark, Llc Methods of prophylaxis of coronavirus infection and treatment of coronaviruses

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA1275922C (en) * 1985-11-28 1990-11-06 Harunobu Amagase Treatment of cancer
SE8703625D0 (sv) * 1987-09-18 1987-09-18 Kabivitrum Ab New medical use
EP0346429B1 (en) * 1987-12-24 1994-12-28 Gropep Pty. Ltd. Peptide analogues of insulin-like growth factor 1 (igf-1) or factor 2 (igf-2)
US5093317A (en) * 1989-06-05 1992-03-03 Cephalon, Inc. Treating disorders by application of insulin-like growth factor
ES2101865T3 (es) * 1991-08-01 1997-07-16 Genentech Inc Igf-1 para mejorar el estado neural.
US5420112A (en) * 1992-06-12 1995-05-30 Lewis; Michael E. Prevention and treatment of peripheral neuropathy

Also Published As

Publication number Publication date
WO1993025219A1 (en) 1993-12-23
JP3623502B2 (ja) 2005-02-23
AU683215B2 (en) 1997-11-06
NO309705B1 (no) 2001-03-19
DK0659083T3 (da) 2000-06-13
ATE187889T1 (de) 2000-01-15
US5648335A (en) 1997-07-15
EP0659083A1 (en) 1995-06-28
DE69327402T2 (de) 2000-05-04
US5569648A (en) 1996-10-29
HUT70450A (en) 1995-10-30
DE69327402D1 (de) 2000-01-27
NZ280523A (en) 1997-07-27
ES2140463T3 (es) 2000-03-01
FI945840A0 (fi) 1994-12-12
JPH07507799A (ja) 1995-08-31
NO944780D0 (no) 1994-12-09
HU217543B (hu) 2000-02-28
EP0659083A4 (en) 1996-03-20
CA2136969A1 (en) 1993-12-23
AU4526293A (en) 1994-01-04
HU9403544D0 (en) 1995-02-28
NZ253867A (en) 1996-08-27
CA2136969C (en) 2009-03-24
PT659083E (pt) 2000-05-31
GR3032844T3 (en) 2000-07-31
US5633228A (en) 1997-05-27
EP0659083B1 (en) 1999-12-22

Similar Documents

Publication Publication Date Title
NO944780L (no) Forhindring og behandling av perifer neuropati
DE69427869D1 (de) Botulinumtoxine zur behandlung von hyperhydrosis
EP0666753A4 (en) METHOD FOR TREATING COMPLICATIONS AND PATHOLOGY AT DIABETES.
DK0436469T3 (da) Præparat og fremgangsmåde til behandling af osteoporose i pattedyr
DE69232410D1 (de) Extern kontrolliertes system zur anrufbehandlung
BR9206070A (pt) Processo para tratar vidro de fluoroaluminossilicato, vidro de fluoroaluminossilicato tratado e alcoxissilanos poliméricos etilenicamente insaturados.
AU7868094A (en) Treatment for nylon and other textiles
EP0579453A3 (en) Composition for masonry treatment and process.
BG102797A (en) The carboznhydrase inhibitor application for the treatment of the maculate oedema
ZA937244B (en) Use of IL-10 to prevent or treat insulin-dependentdiabetes mellitus
NZ247406A (en) Treatment of osteoporosis with 1 alpha, 24(r)-dihydroxy-22(e)-dehydro-vitamin d3
GB2271509B (en) Antivenom immunesera
IL109419A0 (en) Enzyme compositions for the treatment of sticky cotton fiber and method for treating them with such enzyme compositions
AU1429792A (en) Method for the treatment of the sewages and respective plant
DE59103291D1 (de) Verfahren zur bekämpfung von samen- und/oder bodenbürtigen schaderregern durch saatgutbehandlung.
FR2690330B1 (fr) Dispositif destine a traiter certaines fractures siegeant entre massif trochanterien et 1/3 moyen de la diaphyse femorale.
ZA932956B (en) Substrate treatment method and apparatus.
IL102553A0 (en) Agents and process for seed treatment
EP0614364A4 (en) METHODS AND COMPOSITIONS FOR TREATING INFECTIONS USING OPTICALLY PURE (S) -LOMEFLOXACIN.
UA22037A (uk) Спосіб лікуваhhя виразкової хвороби шлуhка та дваhадцятипалої кишки
IL99887A0 (en) Process for treating and disinfecting water
ZA934102B (en) Timber treatment process
ZA965345B (en) Methods of treating neuropeptide Y-associated conditions.

Legal Events

Date Code Title Description
MK1K Patent expired